ROSSELL-TECHSYS
10.11.2021 18:54:04 CET | Business Wire | Press release
Rossell Techsys has been awarded a contract with Lockheed Martin to build Electrical Wire Harness and Interconnect System (EWIS) parts in support of Lockheed Martin’s MH-60R aircraft that are being supplied to the Indian Navy. Last year, India signed a USD $2.1 billion deal with the United States Government as part of its Foreign Military Sales program for the purchase of 24 Lockheed Martin anti-submarine MH-60R helicopters. The first three of these MH-60R all-weather helicopters, which can support multiple missions with state-of-the-art avionics and sensors, have been delivered to the Indian Navy and are currently undergoing pilot and crew training in the United States. The delivery of 24 helicopters will be completed in five years from the time the deal was concluded. The helicopters will be modified with a variety of "India-unique" equipment and weapons. The induction of these fourth-generation MH-60Rs is expected to further enhance the Indian Navy's three-dimensional capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110006132/en/
“We are honoured to have been selected to manufacture wire harnesses for the MH-60R, an important equipment for India. We are committed to producing high-quality parts, on time, from India, furthering India’s growing strength in manufacturing to global standards and contributing to Aatmanirbhar Bharat ,” said Mr. Prabhat Kumar Bhagvandas, Chief Executive Officer, Rossell Techsys.
As part of the contract received from Lockheed Martin, Rossell Techsys shall perform “Build to Print” (BTP) manufacture of the wire harnesses that will be installed on the MH-60R. Manufacture of these parts is being performed in the “Center of Excellence” (COE), set up by Rossell Techsys for Lockheed Martin platforms. The manufacture of parts has commenced, with the first parts having successfully undergone acceptance by Lockheed Martin. The contract shall also enable Lockheed Martin to obtain offset credits towards this platform sale.
“We are excited about the opportunity to partner with Rossell Techsys and confident of their vital capability to deliver high quality cable and harness assemblies in support of the India MRH Program and the Indian Navy,” said Hamid Salim, Vice President and General Manager, Sikorsky Maritime and Mission Systems.
About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin Corporation is a global security and aerospace company that employs approximately 114,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.
Present in India for over three decades, Lockheed Martin is proud of its longstanding relationships and commitment to customers and partners on existing and future programs ranging from transport, maritime and fighter aircraft, to sea and land-based air and missile defence projects, as well as capabilities in civil sectors including new and renewable energy. A strategic partner and developer of sovereign industrial, workforce and enterprise capability, Lockheed Martin India’s joint ventures, apprenticeships, and founding membership of the India Innovation Growth Program underscore its conviction in Indian industry, talent and progress.
Please follow @LMNews on Twitter for the latest announcements and news across the company.
About Rossell Techsys
Rossell Techsys is the Aerospace & Defense Division of Rossell India Limited, a public listed company. It is an MSME, certified to AS9100, ISO 9001, ISO 14001, ISO 45001, ISO 27001, ISO 37001 and is also ISO 31000 and NIST 800-171 compliant. It operates from a state-of-the-art 225,000 sq. ft., LEED Gold rated facility at Bangalore, providing custom engineering and manufacturing services. Core competencies are in Electrical Wiring and Interconnect Systems (EWIS), Electronic System and Systems Integration (ESSI), Test Equipment and After Market Product Support Services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110006132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom